Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Cresco Labs Inc.
  6. News
  7. Summary
    CL   CA22587M1068

CRESCO LABS INC.

(CL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cresco Labs : CEO talks legal marijuana industry challenges

10/18/2020 | 10:11am EDT

LOS ANGELES — Demand for marijuana products in U.S. states where they are legal in some form has been resilient this year, despite the pandemic.

In California and other states that account for most of the retail sales of marijuana for recreational use, sales are up 8.5% from a year ago, according to data from industry tracker Headset.

Charlie Bachtell, CEO and co-founder of Chicago-based Cresco Labs, credits strong sales this year to growing marijuana demand and retailers having been deemed essential businesses during the pandemic.

Cresco Labs began growing and selling marijuana in Illinois in 2015, and as of this year has expanded to a total of nine states and Canada. Its sales more than tripled in the first half of this year to nearly $161 million. Its stock trades on the Canadian stock exchange and on over the counter markets in the U.S.

Only 11 states including Oregon and Colorado allow the retail sales of marijuana for recreational use, but advocates are pushing to expand access elsewhere. The pandemic has ravaged states’ finances, making legalizing marijuana -- and collecting high excise sales taxes -- more appealing to state governments. Six states will vote on marijuana-related ballot initiatives in next month's elections.

Bachtell recently spoke to The Associated Press about how Cresco has prospered during the pandemic and the challenges facing the U.S. cannabis industry. The interview has been edited for length and clarity.

Q: How have your sales fared during the pandemic and recession?

A: The easiest way for me to describe it is to compare second-quarter results to first-quarter results. We’re in nine markets across the country, nine different states, and we saw at least 30% sequential growth, quarter-over-quarter, in all of our nine states except for one, Massachusetts. And Massachusetts was one of the very limited states that did not deem the adult-use program essential.

Q: Would you say the pandemic's been a boon for legal marijuana, given so many people are sheltering in place and looking for ways to manage the stress of it all?

A: You can find the correlation there, for sure. They have more time on their hands, working from home, being at home, and finding something else to help them take their mind off the stress. All of the above are factors in what we saw with greater acceptance, a greater consumer base with greater spending, so far, during this era. We tend to be in the highly regulated newer markets -- Illinois, Pennsylvania, Ohio, New York -- but they’re seeing growth in well-established markets like Colorado, Washington, Oregon and California. To see growth in those markets is even more telling.

Q: What’s the biggest challenge facing the industry?

A: The main thing holding the industry back is access to capital that would allow the infrastructure to be built, that then creates the growth, the jobs, the revenue. The fundamental restraint that still hangs over this industry is it’s difficult to capitalize it, but once that hurdle is cleared, even if nothing else is done, you’ll see explosive growth.

Q: The SAFE Banking Act, which would free up banks to do business with licensed marijuana companies, has stalled in the GOP-controlled Senate. How confident are you this and other measures favoured by the cannabis industry will become law in the near future?

A: The conversations are changing from ‘Why would we do this?’ to ‘Why wouldn’t we do this?’ Even at the federal level, as it relates to how banking occurs, you’ll find support for this on both sides of the aisle. And it’s less about ‘if’ and more about ‘how’ to do it. Cannabis, from my perspective, is in a very good position.

© 2020 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about CRESCO LABS INC.
06/11CRESCO LABSá : NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD O..
PU
06/09CRESCO LABSá : Diversifies Edibles & Vape Portfolio Through Good News Brand Expa..
BU
06/08Update on Piper Sandler Hosted Cannabis Management Teams; 4th of 4 parts
MT
06/08Update on Piper Sandler Hosted Cannabis Management Teams; 3rd of 4 parts
MT
06/08Update on Piper Sandler Hosted Cannabis Management Teams; 2nd of 4 parts
MT
06/08Piper Sandler Hosted Cannabis Management Teams; Finds US Outlook "Remains Rob..
MT
05/27CRESCO LABSá : Announces First Quarter 2021 Financial Results Under U.S. GAAP
BU
05/21CRESCO LABSá : Announces the Appointment of Sidney Dillard to Its Board of Direc..
BU
05/10Pot producer Trulieve to buy Harvest Health for $2.1 bln
RE
05/05EXCLUSIVE : Credit Suisse stops custodian service for some U.S. cannabis stocks ..
RE
More news
Financials (USD)
Sales 2021 842 M - -
Net income 2021 22,7 M - -
Net Debt 2021 58,7 M - -
P/E ratio 2021 203x
Yield 2021 -
Capitalization 3 815 M 3 816 M -
EV / Sales 2021 4,60x
EV / Sales 2022 3,01x
Nbr of Employees 2 700
Free-Float 56,5%
Chart CRESCO LABS INC.
Duration : Period :
Cresco Labs Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRESCO LABS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 23,32 CAD
Last Close Price 13,96 CAD
Spread / Highest target 144%
Spread / Average Target 67,0%
Spread / Lowest Target 28,9%
EPS Revisions
Managers and Directors
NameTitle
Charles Bachtell Chief Executive Officer & Director
Dennis Marin Olis Chief Financial Officer
Thomas Joseph Manning Executive Chairman
Mo Dastagir Chief Information Officer
Ty Gent Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
CRESCO LABS INC.11.24%3 816
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857